Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842672 · ClinicalTrials.gov registry record · Phase 1
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
A Phase 1 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01842672: Completed Phase 1 study, sponsored by New York Medical College.
NCT01842672 is a Phase 1 study that has completed, run by New York Medical College. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01842672, a Phase 1 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).
Primary Outcome
2.1 To determine the maximal tolerated dose (MTD) and/or tolerable dose of escalating doses of clofarabine starting from 20mg/m2/day to 40mg/m2/day from Day 1 to Day 5 in combination with mitoxantrone 12mg/m2/day on Day 3-6 as reinduction therapy for children, adolescents and young adults with poor risk refractory/relapsed acute leukemia or high grade NHL.
Interventions
- DRUG Mitoxantrone
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-03 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
What the finished NCT01842672 record still lists
NCT01842672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Mitoxantrone is the first listed.
NCT01842672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01842672 about?
NCT01842672 is a clinical study titled "Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia". The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).
What is the current status of trial NCT01842672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2013-03. Estimated completion is 2022-09.
What interventions are being tested in trial NCT01842672?
The interventions under investigation include: Mitoxantrone (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT01842672?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01842672's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia